Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are in high demand in Qatar due to the high prevalence of respiratory diseases in the country.
Customer preferences: Bronchodilator drugs are preferred by customers who suffer from respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. These drugs are used to relax the muscles in the airways, making it easier to breathe. Customers in Qatar prefer bronchodilator drugs that are fast-acting and have minimal side effects.
Trends in the market: The bronchodilator drugs market in Qatar is expected to grow in the coming years due to the increasing prevalence of respiratory diseases. The market is also driven by the growing elderly population who are more susceptible to respiratory diseases. The demand for bronchodilator drugs is also expected to increase due to the high levels of air pollution in Qatar. Customers are increasingly looking for natural bronchodilator alternatives such as herbal remedies.
Local special circumstances: Qatar has a high prevalence of respiratory diseases due to factors such as air pollution, smoking, and a dry climate. The country has a high incidence of asthma and COPD, with a significant number of hospital admissions and deaths related to these diseases. Qatar has taken steps to reduce air pollution, including the implementation of stricter regulations on vehicle emissions and the use of renewable energy sources.
Underlying macroeconomic factors: The healthcare sector in Qatar is rapidly expanding, with the government investing heavily in healthcare infrastructure and services. The country has a high per capita income, which enables customers to afford expensive medications. The high prevalence of respiratory diseases and the aging population are expected to drive demand for bronchodilator drugs in the coming years. The government has also implemented measures to promote healthy living, including smoking cessation programs and public awareness campaigns.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
